2. Search Result
Search Result
Results for "

JIMT-1

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153065
    KIF18A-IN-6

    		Kinesin Microtubule/Tubulin Cancer
    KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity [1].
    KIF18A-IN-6
  • HY-153066
    VLS-1272

    KIF18A-IN-7

    		 Kinesin Microtubule/Tubulin Apoptosis Cancer
    VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC50 = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CIN High tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research [1] .
    VLS-1272
  • HY-P99030
    Margetuximab

    MGAH-22

    		 EGFR Cancer
    Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer [1].
    Margetuximab
  • HY-161781
    HVH-2930

    		HSP EGFR Akt Survivin Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    HVH-2930 is a HSP90 C-terminal domain inhibitor with high oral bioavailability. HVH-2930 downregulates HSP90 client proteins, inhibits the HER2 signaling pathway, induces apoptosis, and suppresses the proliferation of breast cancer cells. HVH-2930 inhibits the proliferation of tumors sensitive or resistant to Trastuzumab (HY-P9907). HVH-2930 is applicable to relevant research on breast cancer [1].
    HVH-2930
  • HY-P99969
    Inetetamab

    CMAB-302; Cipterbin

    		 EGFR Cancer
    Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities [1] .
    Inetetamab
  • HY-152208
    BPDA2

    		SHP1 SHP2 Cancer
    BPDA2 is a highly selective and competitive active site SHP2 inhibitor with IC50s of 92.0 nM, 33.39 μM, 40.71 μM for SHP2, SHP1, SHP1B, respectively. DBDA2 downregulates mitogenic and cell survival signaling and RTK expression. BPDA2 suppresses SHP2 mediated signaling and breast cancer cell phenotypes [1].
    BPDA2
  • HY-N1305
    Sideritoflavone

    Sideritiflavone

    		 Others Cancer
    Sideritoflavone is a flavonoid. Sideritoflavone can be isolated from Baccharis densiflora. Sideritoflavone is toxic to JIMT-1 breast cancer cells [1].
    Sideritoflavone
  • HY-177787A
    2'-Deoxy-N-methyl-AMP ammonium

    		Nucleoside Antimetabolite/Analog Others
    2'-Deoxy-N-methyl-AMP ammonium is an N6-substituted adenine nucleotide derivative and a glycosyl donor. On one hand, 2'-Deoxy-N-methyl-AMP ammonium acts as a specific substrate for N6-methyl-AMP aminohydrolase, and it is catalytically converted to dIMP to participate in the nucleotide metabolic cycle. On the other hand, 2'-Deoxy-N-methyl-AMP ammonium also serves as a guanosine diphosphate (GDP)-linked fucose derivative donor, driving site-specific glycoconjugation of proteins under the mediation of α-1,3-fucosyltransferase. 2'-Deoxy-N-methyl-AMP ammonium is an important molecular tool for investigating the mechanisms of nucleotide modification and protein glycosylation [1] .
    2'-Deoxy-N-methyl-AMP ammonium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: